IRVINE, Calif.--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company focused on the treatment of Acute Myocardial Infarction (AMI), released results from the company’s multicenter Investigational Device Exemption (IDE) pilot study that showed a 9.6% infarct size at 30 days in high-risk patients treated with its next-generation system for Supersaturated Oxygen (SSO2) Therapy. This groundbreaking therapy is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients. The study results were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
Help employers find you! Check out all the jobs and post your resume.
